In addition, according to the recent 2021 WHO classification of tumors of the central nervous system (CNS) [6], previously called IDH-mutant GBM, is now designated as IDH-mutant grade 4 astrocytoma, and GBM is diagnosed in the setting of IDH-wild-type status. The gene discussed is IDH2; the disease is glioblastoma.